Literature DB >> 19066838

[Value of retroperitoneal lymphadenectomy for germ cell cancer].

S Krege1.   

Abstract

Retroperitoneal lymph node dissection (RPLND) is an integral part in the therapy of nonseminomatous germ cell tumors. However, there has been a shift concerning the indication. For a long period RPLND was the primary choice in clinical stage I nonseminoma. Nowadays a risk-adapted strategy is preferred. RPLND is obligatory after finishing chemotherapy in metastasized patients if residual tumor is seen. In cases of a late relapse surgery is much more important than chemotherapy independent of increased tumor markers. RPLND can also be a salvage strategy in chemoresistant patients. About 25% of these patients have a long-term benefit. Open or laparoscopic surgery can be performed, though the indications for laparoscopy are small.

Entities:  

Mesh:

Year:  2009        PMID: 19066838     DOI: 10.1007/s00120-008-1757-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  27 in total

1.  Laparoscopic retroperitoneal lymph node dissection: description of the nerve-sparing technique.

Authors:  Reinhard Peschel; Matthew T Gettman; Richard Neururer; Alfred Hobisch; Georg Bartsch
Journal:  Urology       Date:  2002-08       Impact factor: 2.649

2.  Laparoscopic retroperitoneal lymphadenectomy in the management of low-stage testicular cancer: technique and results.

Authors:  S Corvin; W Sturm; M Kuczyk; A G Anastasiadis; A Stenzl
Journal:  Minim Invasive Ther Allied Technol       Date:  2005       Impact factor: 2.442

3.  Laparoscopic retroperitoneal lymphadenectomy after chemotherapy for stage IIB nonseminomatous testicular carcinoma.

Authors:  G Janetschek; A Hobisch; A Hittmair; L Höltl; R Peschel; G Bartsch
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

4.  Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome.

Authors:  G Janetschek; A Hobisch; R Peschel; A Hittmair; G Bartsch
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

5.  Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.

Authors:  Ellen A Ronnen; G Varuni Kondagunta; Jennifer Bacik; Stephanie Marion; Dean F Bajorin; Joel Sheinfeld; George J Bosl; Robert J Motzer
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

6.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.

Authors:  R T D Oliver; M D Mason; G M Mead; H von der Maase; G J S Rustin; J K Joffe; R de Wit; N Aass; J D Graham; R Coleman; S J Kirk; S P Stenning
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

7.  [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial.

Authors:  M de Wit; W Brenner; M Hartmann; J Kotzerke; D Hellwig; J Lehmann; C Franzius; S Kliesch; M Schlemmer; K Tatsch; R Heicappell; L Geworski; H Amthauer; B M Dohmen; H Schirrmeister; U Cremerius; C Bokemeyer; R Bares
Journal:  Ann Oncol       Date:  2008-05-02       Impact factor: 32.976

8.  Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.

Authors:  A G Aprikian; H W Herr; D F Bajorin; G J Bosl
Journal:  Cancer       Date:  1994-08-15       Impact factor: 6.860

9.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz-Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

Review 10.  European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

Authors:  Susanne Krege; Jörg Beyer; Rainer Souchon; Peter Albers; Walter Albrecht; Ferran Algaba; Michael Bamberg; István Bodrogi; Carsten Bokemeyer; Eva Cavallin-Ståhl; Johannes Classen; Christoph Clemm; Gabriella Cohn-Cedermark; Stéphane Culine; Gedske Daugaard; Pieter H M De Mulder; Maria De Santis; Maike de Wit; Ronald de Wit; Hans Günter Derigs; Klaus-Peter Dieckmann; Annette Dieing; Jean-Pierre Droz; Martin Fenner; Karim Fizazi; Aude Flechon; Sophie D Fosså; Xavier Garcia del Muro; Thomas Gauler; Lajos Geczi; Arthur Gerl; Jose Ramon Germa-Lluch; Silke Gillessen; Jörg T Hartmann; Michael Hartmann; Axel Heidenreich; Wolfgang Hoeltl; Alan Horwich; Robert Huddart; Michael Jewett; Johnathan Joffe; William G Jones; László Kisbenedek; Olbjørn Klepp; Sabine Kliesch; Kai Uwe Koehrmann; Christian Kollmannsberger; Markus Kuczyk; Pilar Laguna; Oscar Leiva Galvis; Volker Loy; Malcolm D Mason; Graham M Mead; Rolf Mueller; Craig Nichols; Nicola Nicolai; Tim Oliver; Dalibor Ondrus; Gosse O N Oosterhof; Luis Paz Ares; Giorgio Pizzocaro; Jörg Pont; Tobias Pottek; Tom Powles; Oliver Rick; Giovanni Rosti; Roberto Salvioni; Jutta Scheiderbauer; Hans-Ulrich Schmelz; Heinz Schmidberger; Hans-Joachim Schmoll; Mark Schrader; Felix Sedlmayer; Niels E Skakkebaek; Aslam Sohaib; Sergei Tjulandin; Padraig Warde; Stefan Weinknecht; Lothar Weissbach; Christian Wittekind; Eva Winter; Lori Wood; Hans von der Maase
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.